Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - October 2017

ADME PK

The industry has been eagerly awaiting the new FDA guidance on DDI studies. Last week, the draft guidance was finally released! The guidance has now been separated into in vitro drug-drug interaction studies and clinical drug interaction studies. We will be updating our popular ADME and DDI guides shortly to incorporate the changes. You can download the new guidance for in vitro DDI studies below.

Assessing genotoxicity is an integral part of the preclinical drug development process and is a regulatory requirement prior to the approval of new drugs. However, flagging genotoxic liability at this late stage is a concern and many companies are now taking a more cautious approach by testing earlier in drug discovery. To address this need, Cyprotex have developed a genotoxicity screening approach using the biomarkers pH3 and pH2AX. This approach not only identifies genotoxicity but also helps to understand the mechanism underlying the genotoxicity by differentiating between clastogens and aneugens. More information about this service is detailed below.

Metformin is the first line treatment for type 2 diabetes and, as such, is a common co-medication in patients due to the prevalence of diabetes as a comorbidity in many disease areas. Elevated plasma concentrations of metformin have been associated with lactic acidosis, and so drug-drug interactions (DDI) involving metformin are of clinical concern. In a recent publication by Elsby et al., (2017) in Pharmacology Research & Perspectives, further investigation into the mechanism behind metformin DDI is presented. You can download the publication below.

Finally, in October, our parent company, Evotec, announced yet another success in its industrial drug discovery collaborations by reaching its first milestone in its neurodegeneration alliance with Celgene. The company also announced a three year integrated drug discovery collaboration with Tesaro to discover and develop novel small molecules in the field of immuno-oncology. Find out more below.

New draft FDA guidance on drug-drug interaction studies

In October 2017, the new draft FDA guidance documents on DDI studies were finally released. The guidance has now been separated into in vitro drug-drug interaction studies and clinical drug interaction studies. We will be updating our popular ADME and DDI guides shortly to incorporate the changes.

You can download the new guidance for in vitro DDI studies below.

Download

Download
 
New pH3 and pH2AX screening service for genotoxicity

Learn more about our new genotoxicity service which uses high content screening to detect DNA damage and differentiation of clastogens and aneugens through pH3 and pH2AX biomarkers.

Learn more

Learn more
 
Download our recent publication on metformin DDI

Our recent publication by Elsby et al., (2017) in Pharmacology Research & Perspectives provides further insight into the mechanism behind metformin transporter interactions. Download our publication for free.

Download publication

Download publication
 
Highlights from our parent company, Evotec

Evotec have been collaborating with Celgene through a strategic alliance in the area of neurodegenerative disease. The first milestone in the project has been reached following the successful completion of a screening campaign using Evotec's iPSC-based screening platform.

Learn more

Evotec have announced a three year integrated drug discovery collaboration with Tesaro to discover and develop novel small molecules in the field of immuno-oncology.

Learn more


Learn more
 
Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close